May Health has received CE Mark certification under the European Union Medical Device Regulation for its Anavi System, an ultrasound-guided, office-based radiofrequency device intended to restore ovulation in women with polycystic ovary syndrome-related infertility who do not respond to first-line pharmacologic therapies. The clearance allows commercial rollout across European Union markets and is supported by safety and feasibility data from the ULTRA clinical studies, positioning the device between drug therapy failure and escalation to in vitro fertilization or laparoscopic surgery.

Why this regulatory milestone matters more than it first appears

At face value, the CE Mark is a regional regulatory event. In practice, it reopens a long-neglected therapeutic middle ground in reproductive endocrinology. For decades, clinical pathways for polycystic ovary syndrome-related infertility have followed a blunt sequence: ovulation-inducing drugs first, followed by either laparoscopic ovarian drilling or assisted reproductive technologies when medications fail. Industry observers note that while pharmacologic induction is effective for many patients, a substantial minority either do not respond or discontinue care when the next steps become invasive, expensive, or emotionally burdensome.

The Anavi System attempts to reframe this escalation curve by translating a historically surgical concept into an office-based intervention. That shift matters operationally as much as clinically. A one-time, outpatient procedure alters referral dynamics, clinic economics, and patient willingness to continue treatment, especially in European health systems where access to in vitro fertilization can be limited by reimbursement caps or long waiting lists.

What is genuinely new versus what builds on established practice

Clinicians tracking the field emphasize that the biological concept behind the Anavi System is not novel. Laparoscopic ovarian drilling has long demonstrated that selective ablation of ovarian tissue can restore ovulatory cycles in women with polycystic ovary syndrome by modulating androgen production and intra-ovarian signaling. What has changed is the delivery mechanism.

The Anavi System replaces laparoscopic access with ultrasound-guided radiofrequency energy delivered in an office setting. This removes general anesthesia, operating room time, and surgical recovery, while preserving the core physiological intent. From a device innovation standpoint, this is an enabling technology rather than a mechanistic breakthrough. Its value proposition rests on procedural accessibility, repeatability, and safety rather than a new biological pathway.

That distinction is important for regulators and payers. Incremental delivery innovation typically faces a different evidentiary burden than first-in-class therapies, but it also competes directly with entrenched standards of care that already have decades of outcome data.

How the clinical data should be interpreted cautiously

The CE Mark decision is supported by data from the ULTRA studies conducted in Europe and the United States. According to investigators, the majority of evaluable patients reported ovulation within 12 months, with a meaningful proportion achieving pregnancy, including spontaneous conceptions. Adverse events were reported as mild and procedural in nature.

Regulatory watchers caution, however, that these data are early-stage and exploratory. The studies were designed for safety and feasibility rather than definitive comparative efficacy. There is no randomized comparison against laparoscopic ovarian drilling, optimized pharmacologic regimens, or direct progression to assisted reproductive technologies. Ovulation restoration, while clinically relevant, is also a surrogate outcome that does not fully capture long-term reproductive success, recurrence rates, or metabolic implications.

The ongoing REBALANCE study in the United States will be more consequential. Its randomized, controlled design will likely define how regulators, clinicians, and payers assess durability of benefit, reproducibility across centers, and positioning within treatment guidelines.

Where this fits relative to existing infertility interventions

From a pathway perspective, the Anavi System positions itself after first-line ovulation induction but before surgical or assisted reproductive escalation. This intermediate slot has historically been thinly populated, largely because laparoscopic ovarian drilling requires operating room infrastructure and carries surgical risk that many patients and clinicians prefer to avoid.

If the Anavi System delivers consistent outcomes in broader use, it could become a default second-line option for women with polycystic ovary syndrome who are medication-resistant or medication-averse. That would represent a meaningful shift in practice patterns, particularly in fertility clinics seeking to reduce drop-off between failed drug therapy and in vitro fertilization referral.

Comparatively, assisted reproductive technologies remain more effective on a per-cycle basis but come with higher cost, complexity, and emotional burden. The Anavi approach does not compete directly with in vitro fertilization on success rates; instead, it competes on willingness to proceed, affordability, and alignment with patients seeking less intensive intervention.

Regulatory implications beyond Europe

CE Mark approval under the European Union Medical Device Regulation carries strategic weight beyond immediate commercialization. Europe increasingly functions as an early proving ground for women’s health devices that face more complex regulatory and reimbursement pathways in the United States.

Success in European markets can generate real-world evidence on utilization, clinician learning curves, and patient selection that informs U.S. regulatory submissions. The REBALANCE study is designed to support U.S. Food and Drug Administration review, but regulators are likely to scrutinize whether outcomes observed in controlled trials translate into consistent benefit across diverse practice settings.

Regulatory observers also note that device-based fertility interventions often face questions around training requirements, operator variability, and post-market surveillance. These factors will shape how quickly and broadly the Anavi System can scale.

Adoption and reimbursement challenges that remain unresolved

Even with regulatory clearance, commercial success is not assured. Fertility care sits at the intersection of specialty medicine, elective procedures, and variable reimbursement structures. In many European markets, reimbursement decisions will be made at the national or regional level, with cost-effectiveness assessments weighing the device against drug therapy continuation or direct progression to assisted reproductive technologies.

Clinics will also evaluate workflow integration. An office-based procedure requires investment in equipment, staff training, and patient counseling. While the absence of surgery is a clear advantage, fertility specialists will need confidence that outcomes justify changing established protocols.

Industry analysts also flag patient selection as a potential friction point. Identifying which women with polycystic ovary syndrome are most likely to benefit, and when in the treatment journey the procedure should be offered, will determine real-world performance.

What clinicians and regulators are likely to watch next

Attention will focus on durability of ovulation restoration, rates of repeat intervention, and downstream pregnancy outcomes. Regulators will watch adverse event reporting as use expands beyond controlled studies. Clinicians will track whether the procedure alters long-term ovarian reserve or complicates future assisted reproductive interventions.

There is also broader interest in whether this approach could normalize ovulatory function without creating new metabolic or endocrine trade-offs, a concern that has followed surgical ovarian interventions historically.

From an industry perspective, the Anavi System may signal renewed interest in device-led solutions for conditions traditionally managed with drugs or surgery. If successful, it could encourage investment in similarly positioned technologies that bridge therapeutic gaps rather than compete head-on with pharmaceutical or assisted reproductive incumbents.

The broader signal for women’s health innovation

Beyond polycystic ovary syndrome, the CE Mark approval reflects growing regulatory openness to device-based solutions in women’s health, a field long underserved by innovation capital. Analysts note that scalable, office-based interventions addressing quality-of-life and reproductive outcomes are increasingly attractive as healthcare systems seek cost containment without compromising care.

Whether the Anavi System becomes a category-defining tool or a niche option will depend on execution, evidence generation, and clinician trust. What is clear is that it reintroduces choice into a treatment pathway that has remained structurally rigid for years.

  Anavi System, CE Mark, fertility treatment, May Health, medical devices, PCOS infertility, polycystic ovary syndrome, reproductive endocrinology, women’s health devices